Analyst Ratings January 30, 2026

H.C. Wainwright Lifts Alnylam Price Target Citing TTR Franchise and 'Alnylam 2030' Plan

Analyst revises estimates while reaffirming Buy rating as company reports robust revenue growth and sets 2026 revenue goal

By Hana Yamamoto ALNY
H.C. Wainwright Lifts Alnylam Price Target Citing TTR Franchise and 'Alnylam 2030' Plan
ALNY

H.C. Wainwright raised its price objective on Alnylam Pharmaceuticals to $510 from $470 and kept a Buy rating, pointing to the scaling of the company’s TTR franchise and its multi-year strategic roadmap as drivers. The firm adjusted forward estimates to reflect post-launch normalization, higher sustained R&D spending and conservative margin assumptions, while finding no sign of weakened demand for AMVUTTRA. The update comes alongside Alnylam's preliminary Q4 2025 revenues and multiple peer analyst target adjustments.

Key Points

  • H.C. Wainwright raised its Alnylam price target to $510 from $470 and kept a Buy rating, citing TTR franchise scaling and the "Alnylam 2030" plan - impacts the healthcare and biotech sectors.
  • The firm lowered some forward estimates to reflect post-launch normalization, higher sustained R&D spending and more conservative long-term margins as RNAi development moves beyond the liver - affecting R&D-driven biotechnology valuations.
  • Alnylam reported strong revenue momentum with 53.24% year-over-year growth and pre-announced Q4 2025 net product revenues of about $996 million; the company set a $5.1 billion revenue goal for 2026, above consensus.

H.C. Wainwright increased its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $510.00 from $470.00 and reiterated a Buy rating, citing the expanding traction of Alnylam's transthyretin (TTR) franchise and the firm's "Alnylam 2030" strategic framework.

The research note, issued on Friday, positions the new target as a substantial increase relative to Alnylam's then-current share price of $346.79. InvestingPro data referenced by the firm shows analyst price objectives across the sector ranging from $310 to $580.

H.C. Wainwright said its reassessment followed a management call on January 27 that provided additional detail on the five-year strategic outlook first presented on January 11. Following that dialogue, the firm tempered some forward projections to align with expectations for a normalization in quarterly growth after product launches, a sustained uplift in investment in research and development and more conservative long-term margin assumptions as the company advances RNA interference therapeutics beyond liver targets.

Importantly, the research team reported no indication that underlying demand for treatment of ATTR-CM has softened, nor that AMVUTTRA (vutrisiran) has lost competitive position. Instead, the adjustments to estimates reflect timing shifts, anticipated gross-to-net dynamics and the practical difficulties of scaling what the firm characterizes as a potential blockbuster franchise.

Those estimate adjustments sit alongside Alnylam's recent top-line momentum: the company achieved 53.24% revenue growth over the prior twelve months, a figure cited by H.C. Wainwright. InvestingPro also highlighted that Alnylam trades at a notably high price-to-earnings multiple of 1050, reflecting the market's valuation of the company's growth prospects.

H.C. Wainwright described Alnylam as offering an attractive risk-reward profile based on sustained TTR leadership, visible multi-year revenue expansion and long-duration optionality within its pipeline. The firm signaled that shares were trading beneath what it judged intrinsic value to be. Separately, InvestingPro's analysis suggested the stock is slightly undervalued and assigned an overall financial health score of 2.87, graded as "GOOD."

Investors were reminded that Alnylam's next scheduled earnings release is set for February 12, noted as 13 days away from the time of the research update.


In related company disclosures, Alnylam pre-announced fourth quarter 2025 net product revenues of approximately $996 million, marking a 120% year-over-year increase and a 7% sequential gain. That preliminary figure was reported as marginally below analyst expectations.

The company has laid out a revenue target of $5.1 billion for 2026, above the consensus forecast of $4.7 billion, and said a meaningful portion of that growth is expected to be driven by its TTR franchise.

Analyst reactions to Alnylam's results and guidance have been mixed. RBC Capital lowered its target to $465 while retaining an Outperform rating, citing the company's strategic priorities beyond 2026 as a factor in its view. Needham raised its price target to $529, indicating consistency with its own revenue assumptions, even as those revenue figures sat slightly below broader consensus.

BofA Securities adjusted its target to $529 and kept a Buy rating despite a revenue miss for Amvuttra, which produced $827 million in Q4. Cantor Fitzgerald reiterated a Neutral rating, calling out variability in Amvuttra sales as a consideration for the company's confidence in future guidance. Separately, H.C. Wainwright was reported to continue its Buy stance with a $570 price target following the firm's preliminary revenue announcements.

The range of responses from sell-side firms underscores differing interpretations of Alnylam's near-term performance versus its multi-year outlook. H.C. Wainwright's latest move reflects a balance between recognizing the scaling opportunity in the TTR franchise and embedding more cautious operational and margin assumptions into its modeling.

For market participants, the coming earnings release and the company's execution against its 2026 revenue objective will be key near-term data points to watch as analysts and investors reconcile preliminary results with multi-year forecasts.

Risks

  • Gross-to-net dynamics, timing considerations and the complexity of scaling a blockbuster franchise could delay revenue realization - risk for pharmaceutical revenue and healthcare investor returns.
  • Amvuttra sales have shown variability, and preliminary Q4 results slightly missed analyst expectations, creating uncertainty around near-term guidance and market confidence.
  • High valuation measures, such as a P/E of 1050, imply sensitivity to execution; should growth slow relative to expectations, biotech and growth-oriented healthcare stocks could face steep downside.

More from Analyst Ratings

KeyBanc Keeps Cautious View on LyondellBasell After Difficult Quarter, Cites Cash-Flow Limits vs. Dividend Feb 2, 2026 KeyBanc Sticks with Overweight on Murphy USA, Sees Near-Term Upside as Fuel Margins Improve Feb 2, 2026 Bernstein Boosts SanDisk Price Target to $1,000 After Robust Q2; Peers Follow Suit Feb 2, 2026 Piper Sandler Sticks With Overweight on Robinhood as Shares Pull Back Feb 2, 2026 Bernstein Raises Verizon Target to $48, Cites Strong Subscriber and FWA Gains Feb 2, 2026